Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy

Retina

Volumn 29, Issue 6, 2009, Pages 768-774

  Yeh, Po Ting ^a,b   Yang, Chung May ^a,b   Lin, Yu Chi ^a,c   Chen, Muh Shy ^a,b   Yang, Chang Hao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Shin Kong Wu Ho Shu Memorial Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INSULIN DERIVATIVE; SILICONE OIL;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; PREOPERATIVE CARE; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRONE POSITION; PROSPECTIVE STUDIES; RETINAL HEMORRHAGE; RETINAL NEOVASCULARIZATION; SILICONE OILS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 67749147367     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a3b7ef     Document Type: Article

References (23)

1. Shen YD, Yang CM. Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study. Eur J Ophthalmol 2007;17:954-960.
2. Yang CM. Surgical treatment for diabetic retinopathy: 5-year experience. J Formos Med Assoc 1998;97:477-484.
3. Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 2003;87:318-321.
4. Douglas MJ, Scott IU, Flynn HW Jr. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2003;34:270-278.
5. Hoerauf H, Roider J, Bopp S, et al. Endotamponade with silicon oil in severe proliferative retinopathy with attached retina. Ophthalmologe 1995;92:657-662.
6. Oyakawa RT, Schachat AP, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy. I Intraoperative complications. Ophthalmology 1983;90:517-521.
7. Asaria RH, Kon CH, Bunce C, et al. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol 2004;88:1439-1442.
8. Lewis H, Burke JM, Abrams GW, et al. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 1988;95:583-591.
9. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-e15.
10. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
11. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009;23:108-111.
12. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699 -700.
13. Eliott D, Lee MS, Abrams GS. Proliferative diabetic retinopathy: principles and techniques of surgical treatment. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson P, eds. Retina. Vol 3. Surgical Retina. Fourth Edition. Philadelphia: Elsevier Mosby; 2006: 2413-2415.
14. Yeh PT, Yang CM, Yang CH, et al. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study. Ophthalmology 2005;112:2095-2102.
15. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710-715.
16. Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe prolif-erative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-842.
17. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114: 855-859.
18. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
19. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-1904.
20. Schneeberger SA, Hjelmeland LM, Tucker RP, et al. Vascular endothelial growth factor and fibroblast growth factor 5 are colocalized in vascular and avascular epiretinal membranes. Am J Ophthalmol 1997;124:447-454.
21. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403.
22. Morse LS, Chapman CB, Eliott D, et al. Subretinal hemorrhages in proliferative diabetic retinopathy. Retina 1997;17: 87-93.
23. Charles S, Katz A, Wood B. Vitreous Microsurgery. Third Edition. Philadelphia: Lippincott Williams & Wilkins; 2002: 104-125.